PGHL vs ZIMLAB: Stock Comparison

Procter & Gamble Health Limited vs Zim Laboratories Limited

Live data: 22 July 2026, 3:03 PM IST • Source: NSE and company filings

Procter & Gamble Health Limited is the larger company by market capitalisation. Procter & Gamble Health Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Procter & Gamble Health Limited and Zim Laboratories Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, PGHL is more favourable on 12 of 13 scored metrics and ZIMLAB on 1These counts are context-free and are not an overall rating.

Key Differences

Market Cap
PGHL is the larger company
₹11,172 Cr vs ₹656 Cr
P/E Ratio
PGHL has a lower P/E
34.28x vs 112.39x
P/B Ratio
ZIMLAB has a lower P/B
2.21x vs 21.36x
EPS
PGHL has higher earnings per share
₹196.64 vs ₹1.94
Dividend Yield
PGHL has a higher dividend yield
2.34% vs 0.02%
Revenue Growth (TTM YoY)
PGHL has faster revenue growth
19.1% vs -3.36%
EPS Growth (TTM YoY)
PGHL has faster EPS growth
54.6% vs -47.01%
Qtr Sales Growth
PGHL has stronger quarterly sales growth
19.1% vs -12.3%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricPGHLZIMLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricPGHLZIMLAB
Live Price₹6,737₹104.91
Day Change-0.63%0.25%
Volume4,61181,241
52-Week High₹6,975₹121.47
52-Week Low₹4,707₹59.31
Distance from 52W High-3.41%-13.63%

Valuation

MetricPGHLZIMLAB
Market Cap₹11,172 Cr₹656 Cr
P/E Ratio34.28x112.39x
P/B Ratio21.36x2.21x
EPS₹196.64₹1.94
Book Value₹316.01₹51.77
Dividend Yield2.34%0.02%

Growth

MetricPGHLZIMLAB
Revenue Growth (TTM YoY)19.1%-3.36%
EPS Growth (TTM YoY)54.6%-47.01%
Qtr Sales Growth19.1%-12.3%
Qtr Profit Growth54.6%-308%

Profitability & Leverage

MetricPGHLZIMLAB
ROE61.6%1.97%
ROCE83.5%8.16%
Net Margin23.22%1.56%
Operating Margin32.4%5.72%
Debt to Equity0.02x0.42x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricPGHLZIMLAB
Promoter Holding0%30.36% 0.01 pp
FII Holding6.33% 0.13 pp0.03% 0.03 pp
DII Holding12.44% 1.23 pp1.33% 1.26 pp
Public Holding29.42% 1.11 pp68.28% 1.3 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Procter & Gamble Health Limited and Zim Laboratories Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.